OncoMed Pharmaceuticals, Inc.
) announced that it has commenced the third phase Ib study on
pipeline candidate OMP-54F28 with Paraplatin and Taxol in
patients with platinum-sensitive ovarian cancer.
We note that OncoMed is developing OMP-54F28 in collaboration
). OMP-54F28 targets the Wnt pathway. The primary endpoints
of the study are to evaluate safety of this combination regimen
and determine a recommended phase II dose for OMP-54F28 in
combination with Paraplatin and Taxol. Secondary endpoints
include evaluation of the pharmacokinetics (PK) and
pharmacodynamics (PD) of OMP-54F28, as well as the efficacy of
The other two phase Ib studies on OMP-54F28, initiated earlier
this year, are evaluating the candidate with Abraxane and Gemzar
in pancreatic cancer and with Nexavar in hepatocellular
Another Wnt-pathway-targeting compound in the pipeline is
OMP-18R5. In the last quarter of 2013, OncoMed started three
phase Ib studies on OMP-18R5 in patients suffering from non-small
cell lung cancer, Her2-negative breast cancer and stage IV
Currently, all six of OncoMed's planned phase Ib studies for
OMP-18R5 and OMP-54F28 are now in the process of enrolling
patients. All six studies are being conducted under
OncoMed's collaboration with Bayer.
We believe investor focus will remain on updates pertaining to
these studies. We are encouraged by the pipeline progress at
OncoMed currently carries a Zacks Rank #3 (Hold). Investors
looking for better-ranked stocks in the biopharma sector may
consider companies like
Biogen Idec Inc.
). Both carry a Zacks Rank #1 (Strong Buy).
BAYER A G -ADR (BAYRY): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
ENDOCYTE INC (ECYT): Free Stock Analysis
ONCOMED PHARMA (OMED): Free Stock Analysis
To read this article on Zacks.com click here.